



[Home](#) / [Investors](#) / [Press Releases](#)

## Insmmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004

RICHMOND, Va., Mar 16, 2005 (BUSINESS WIRE) -- Insmmed Incorporated (NASDAQ: INSM), a developer of pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs, today announced results for the three and twelve months ended December 31, 2004.

### Discussion of Revenue and Expense Items

Revenues for the three and twelve months ended December 31, 2004 were \$23,000 and \$137,000, respectively, compared with revenues of \$27,000 and \$150,000 for the equivalent periods in 2003. Revenues remained consistent for both the fourth quarter and the twelve-months of 2004 compared to the corresponding periods of 2003.

The net loss for the three and twelve months ended December 31, 2004 was \$5.8 million, or \$0.14 per share and \$27.2 million or \$0.69 per share, respectively. For the three-months ended December 31, 2004, this represents an increase of \$3.4 million or \$0.08 per share from the net loss of \$2.4 million, or \$0.06 per share for the corresponding period in 2003. The increase in the net loss for the quarter compared to the corresponding period in 2003 resulted primarily from a \$3.4 million rise in research and development costs due to the anticipated increase in manufacturing activity to produce SomatoKine(R) for our pivotal Phase III trial in the Growth Hormone Insensitivity Syndrome (GHIS) indication.

For the twelve-months ended December 31, 2004, the increase in net loss was \$16.9 million or \$0.40 per share from the net loss of \$10.3 million, or \$0.29 per share reported for the same period of 2003. The \$16.9 million increase in our net loss for the full year of 2004 as compared with the full year of 2003 resulted mainly from a \$16.2 million escalation in research and development costs and a \$0.6 million rise in general and administration expenses. The former resulted from the planned increase in manufacturing costs to produce SomatoKine(R) for our Clinical trial needs, and the latter due to higher external service and personnel costs in support of our business. The \$66,000 reduction in interest income resulted from a combination of reduced interest rates and a lower cash balance.

### Conference Call

The Company will host a conference call on Thursday, March 17, 2004 at 9:00 a.m. Eastern Time (8:00 a.m. Central Time). Company management will conduct the call and will review the financial and operating results for the fourth quarter and the Company's current activities and expectations for the future. To participate in the conference call, dial 800-946-0722 (domestic) or 719-457-2647 (international). The call will be webcast live through Insmmed's corporate website: [www.insmed.com](http://www.insmed.com). A telephonic replay of the call will be available for one week at 888-203-1112 (domestic) or 719-457-0820 (international) Passcode: 7048463. A web replay of the call will be available through the corporate website beginning at 11:00a.m.

### About Insmmed Incorporated

Insmmed Incorporated is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For further information about Insmmed and rhIGF-I/rhIGFBP-3, please visit the company's corporate website at [www.insmed.com](http://www.insmed.com).

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Although Insmmed believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and various factors may cause its actual results to differ materially from its expectations. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in clinical trials or may not be successfully marketed, the company may lack

financial resources to complete development of product candidates, the company may be unable to raise additional financing necessary to continue current operations, the company may not be able to re-commission our manufacturing facility in Boulder, Colorado that Insmmed leased, and utilize that facility to manufacture the company's product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease and the biopharmaceutical industry may experience negative market trends. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by Insmmed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.

---